HOME > Special Interview on Long-Listed Products and Generic Drugs

Special Interview on Long-Listed Products and Generic Drugs

Astem Pres. Yoshimura Says Wholesalers Should Break Away from Dependence on Long-Listed Drugs

April 4, 2013
MOF Budget Examiner Hirotsugu Shinkawa Hopes to See New Generic Target Set at Highest Share Achievable at Fastest Pace

March 29, 2013
CSIMC Expert Member Yoshiaki Kamoya (Executive Officer, Shionogi) Says Price Cuts for Long-Listed Drugs and Perpetuation of Premium for New Drug Development Should Be Discussed Together

March 22, 2013
Japan Pharmaceutical Association Vice President Hirotsugu Miura Says that 70% Rule for New Generics Will Be Debatable in Future

March 15, 2013
Japan Health Insurance Association President Tsuyoshi Kobayashi Points Out that Price Competition Will Not Work If Prices Are Set Equally

March 12, 2013
Kyoto Medical Association Vice President Hideki Adachi Says Drug Makers Should Closely Verify NHI Prices and Development Costs of Each Drug

March 8, 2013
Shuji Shirakawa of Kenporen Says Long-Listed Product Price Cuts Irrelevant to New Drug Development Premium

February 28, 2013

Upside in Decelerating Gx Arena

Meiji Pharma Pursuing Low-Cost Strategy to Weather Storm in Generics Space, Overseas Plants Hold Key

By Takashi Ebisawa and Tatsuya Otsuka

Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…

My Viewpoint on CEA

Kenporen Director Kono: Apply CEA to Reimbursement Decisions Once Credible System Established

The Japanese cost-effectiveness assessment (CEA) scheme should be applied not only to the price adjustments of drugs and medical devices…

HTA Debates in 2018-2019

Japan to Roll Out Cost-Effectiveness Assessment Scheme in April

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…

TRENDS

Drug Makers on Hunt for “Mibyo” Biz Opportunities as Pricing Rules Get Stricter

By Reiji Anasako

With Japan’s tighter price control casting a chill over its pharma market, companies are setting their sights beyond the field of health insurance to carve out a new revenue stream, seeking opportunities in the business to tackle “mibyo” - a…

COMMENTARY

Generic Makers Shifting to Focus on “Specialty Area” Faced with Tougher Business Environment

By Tatsuya Otsuka

Driven by changes surrounding the Japanese generic drug market, generic companies are trying to shift from a “generic” to a “specialty” model for their main business, with more and more players steering their focus towards specialized areas to secure profits.The…

COLUMN

6 Core Elements of Recruitment Mastery

By Philip Carrigan

Watching a master craftsman at work is a sight to behold.With confidence forged over years of practice, complicated steps appear effortless, problems are smoothly managed, and the final product is perfect, in every sense of the word. Within each of…